ABC | Volume 115, Nº2, August 2020

Editorial Barreto-Filho et al. Uncertainty and Shared Decision Making Arq Bras Cardiol. 2020; 115(2):149-151 From a dogmatic point of view, promoting prescription of drugs before phase III tests should be considered contemporary scientific heresy. Care that is not based on evidence does not necessarily represent good care. The alleged “inertia” of not prescribing a therapy in the absence of supporting evidence is, in most cases, good medical practice. In theory, the pre- test probability of a drug that has never been tested in a determined scenario being effective therein is very remote. Hence the standard of considering experimental clinical trials as the final word. It is not uncommon for hypotheses that are sustained by mechanistic support or observational studies not to be confirmed in randomized trials. A core principle in science is that the burden of proof lies in demonstrating efficacy, rather than inefficacy; for this reason, we begin with the initial premise of scientific thinking, namely, the null hypothesis must be formally rejected in order to prove the phenomenon. The argument that a therapy is safe alone does not justify implementing an ineffective drug. Proof that a benefit exists is a fundamental condition in order to compare a given drug’s positive results with its eventual risks. In the case of CQ/HCQ, we have seen the following situation: The majority of acceptable observational studies have not proven the benefit of the drug. What, then, will serve as a compass for decision making with so much uncertainty and pandemic pressure, in the absence of evidence? First, it is important to underscore that lack of evidence regarding effect does not mean evidence that there is no effect. To deny a potential benefit categorically does not seem to be the best way, either. It is doubtful whether CQ/HCQ has a priori probability that justifies major scientific effort. Nonetheless, even in cases where there is a reasonable likelihood, the first option would be to commit to the task of selecting patients for allocation into clinical trials. Collective, solidary, and articulated efforts could shorten the duration of this uncertainty. When this is not possible, it is understandable, in situations of “war,” to propose off-label use of medications, when a specific drug that has already been properly registered and approved for scenario A is permitted for scenario B without specific studies, or even compassionate use, when a drug that is still experimental and that has not been registered by any regulatory agency is prescribed for lack of a better option in the belief that it might work. It is necessary to underscore that compassionate use is more an act of mercy than a bet on therapeutic success. In the heat of this desperate moment, we are experiencing a pandemonium characterized by the unprecedented proliferation of information of the worst quality, with great variability in the prescription practice observed in the frontlines. In the meanwhile, the guidelines and editorials published in the most prestigious scientific journals have categorically stated that we do not yet have effective etiological therapies that are scientifically proven to reduce the mortality of COVID-19. 1 The treatment of viral pneumonia continues, essentially, to be that of support and intervention in the diverse clinical complications that may arise in a minority of patients. To reinvent knowledge, which is substantially well founded, and to abandon the liturgy of modern clinical science appears to be a great retrogression to the Dark Ages. How, then, shall we make decisions, when uncertainty is the rule? To take an authoritarian or paternalistic stance would not be the wisest path. The current situation in which we find ourselves may perhaps be a unique opportunity to put the principle of patient autonomy into practice, thus enlightening medical decision making. Historically, patients would entrust decision making to physicians. During the last decades, however, patients have been encouraged to take an active role and to participate in decisions about their health. The Crossing the Quality Chasm report, published by the American Institute of Medicine, argues that an active voice should be given to patients in respect to all that will have an impact on their lives. Operationally speaking, this includes transparent information regarding expectations and uncertainties, before shared decision making. Although we understand the complexity of implementing a shared decision-making process during the current situation, the compulsory and indiscriminate prescription of drugs that have no proven efficacy and/ or safety for this scenario does not corroborate the values currently put forth. It is noteworthy that the principle of patient autonomy is an attribute that underpins the basis of the Brazilian Unified Health System, since its foundation, and it is in line with precepts of contemporary Bioethics. Autonomy corresponds to people’s capability to decide in accordance with their own values. The basis of autonomy resides in respect for individuals’ fundamental rights, considering them as biopsychosocial and spiritual beings endowed with the ability to make their own decisions. During a pandemic, when uncertainty becomes even more evident, the return to this fundamental principle of giving patients a voice in the decision table may serve as a bridge whereby the physician-patient binomial will be able to choose the best path, customized to the expectations of the person who is most interested in positive outcomes, namely, the patient. To take full control of all medical decisions and to deceive ourselves with certainties that do not exist can be a sign of immaturity. It is urgent that we transcend the Hippocratic model, wherein physicians are to apply “regimens for the good of patients, according to their knowledge and reason,” leaving no room for their autonomy, to a shared, patient-centered model of care. The current moment calls for professionals who are up-to- date, confident, and open to transparent dialogue on factual evidence in favor of shared decision making. Separating what is scientific evidence, in the midst of so much clinical pseudoscience, will be the cardinal task. Science is not based on faith, belief, opinion, or authority. On the contrary, doubt and uncertainty are the main reasons behind advances in science. It is indispensable to recognize that the consequences of our decisions are not and cannot be shared. Therefore, medical practices for dealing with COVID-19 require humility in that we recognize the boundaries of current scientific knowledge. Transparent sharing of uncertainties and doubts with patients will make it possible to shine a light on the otherwise excessively cumbersome task of making decisions in this scenario, in which there is still too much darkness. This seems to be a significant opportunity to learn today and to bring important lessons to tomorrow in order to pave the way toward the utopia of “medicine that serves patients”. 7 150